|
Bebtelovimab is Available for Purchase Commercially
- As of August 15, 2022, Bebtelovimab has become commercially available for purchase. Orders can be placed directly through AmerisourceBergen.
- USG will allocate the remaining supply of Bebtelovimab to jurisdictions based on populations on September 6, 2022. Providers should not bill patients or insurance for any USG-procured product.
- VDH places a high priority on equitable availability of product. If a facility does not serve the under and/or uninsured, VDH encourages these locations to utilize the redistribution process to reallocate USG product for this vulnerable population.
Guidance on Ordering Bebtelovimab Commercially
A maximum order limit of 270 doses per week per provider site will be imposed. There will be no minimum order quantity. Exceptions for weekly dose quantities beyond 270 will be evaluated on a case-by-case basis. Please note that to limit the potential for overstocking, no returns will be accepted for Bebtelovimab.
Unique batch numbers will differentiate between USG product and commercial product. Review the batch number prior to claim submission to determine if the product was USG-procured or commercially-procured and ensure appropriate billing.
Additional Shelf Life Extension - Sotrovimab
Shelf life extension for all lots of Sotrovimab from 18 months to 24 months. See table 1 below.
Table 1: Extended Expiry Dating for Sotrovimab Authorized under EUA 100
 Current Medicare Payment Structure for Bebtelovimab
- Administration during the Public Health Emergency
- CMS updated COVID-19 Toolkit for Healthcare Providers and Medicare COVID-19 Monoclonal Antibodies Toolkit
- Medicare product payment amount of $2394.00 when sites purchase the product
- No product payment for Bebtelovimab received for free from the USG
- Guidance from the Federal government for commercially acquired product, bill and submit for payment for the drug and the administration cost. If you have USG procured supply, only charge for administration and NOT the drug. Enter $0.01 for the drug.
 [1]Providers shouldn't bill for the product if they received it for free through the USG-purchased inventory.
[1a]Payment rate effective for dates of service on or after August 15, 2022. Providers should only bill Medicare for commercially-purchased products.
[3] These rates will be geographically adjusted for many providers. For providers and suppliers with payments that are geographically adjusted by the methodology used by Medicare Physician Schedule (MPFS), files with the geographically adjusted payment rates for monoclonal antibody administration can be found here. Certain settings utilize other payment methodologies, such as payment based on reasonable costs.
Read more about reimbursement and the table above here.
|
